Silence Therapeutics (SLN) Cash & Current Investments (2018 - 2026)

Silence Therapeutics has reported Cash & Current Investments for 9 years, with the latest figure at $134.5 million in Q1 2026.

• Quarterly Cash & Current Investments fell 35.37% year-over-year to $134.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.5 million (down 35.37% YoY) and the FY2025 annual result came in at $85.1 million, down 54.26% from the prior year.
• Cash & Current Investments improved to $134.5 million in Q1 2026 per SLN's latest filing, from $85.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $208.1 million in Q1 2025 and troughed at $64.3 million in Q4 2022.
• A 5-year average of $122.7 million and a median of $118.3 million in 2025 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments jumped 177.47% in 2024, then sank 54.26% in 2025.
• Over 5 years, Cash & Current Investments stood at $64.3 million in 2022, then advanced by 4.3% to $67.1 million in 2023, then surged by 177.47% to $186.1 million in 2024, then tumbled by 54.26% to $85.1 million in 2025, then jumped by 58.05% to $134.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $134.5 million, $85.1 million, and $122.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.